To capitalize on the treatment-method trend, the first move is to own the public companies that develop and commercialize therapies—leaders in pharma and biotech such as Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Amgen (AMGN), Eli Lilly (LLY), and Roche (RHHBY). Indirect exposure comes from healthcare services and devices that enable treatment delivery, including Medtronic (MDT) and broader healthcare equity plays or ETFs like XLV. Entrepreneurially, opportunities exist in digital health platforms that optimize treatment pathways, AI-assisted clinical decision support, precision medicine tools, and specialty clinics focused on novel therapeutic modalities.